摘要
侵袭性真菌病在恶性血液病化疗和造血干细胞移植患者中发病率及病死率很高。初级预防可有效减少侵袭性真菌病的发生,使患者对化疗和造血干细胞移植的耐受性更佳,治疗费用更低,预后更好。氟康唑、伊曲康唑、泊沙康唑、卡泊芬净、米卡芬净等抗真菌药物已被多个指南推荐用于初级预防。侵袭性真菌病风险预估、新型药物研发、药代动力学研究、综合预防措施的开展将使初级预防更加科学、合理、有效。
Invasive fungal diseases （IFD） are associated with considerable morbidity and mortality in patients with hematological malignancies. Primary antifungal prophylaxis （PAP） is effective for decreasing incidence of IFD, and the patients will be more tolerable to chemotherapy with less cost and better prognosis. Antifungal drugs as fluconazole, itraconazole, posaconazole, caspofungin and micafungin are all recommended for PAP by many consensus and guidelines. The PAP will be more scientific, appropriate and effective with the development of studies about predicting risk-stratification for IFD, new drugs, pharmacokinetics and integrated prophylaxis. This review summarizes the progress of PAP in hematological malignancy patients in recent years.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2017年第2期627-632,共6页
Journal of Experimental Hematology
基金
解放军总医院科技创新苗圃基金面上项目(13KMM01)
关键词
恶性血液病
侵袭性真菌病
抗真菌初级预防
hematological malignancy
invasive fungal disease
primary antifungal prophylaxis
